Default company panoramic image
Homepage banner image

Gamma Therapeutics, Inc.

GT is an early stage biotech start up developing medical devices for cardiovascular disease risk assessment, surgical therapy & hemorrhage control.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Portland, OR, USA
  • Currency USD
  • Founded December 2009
  • Employees 3
  • Incorporation Type C-corp
  • Website

Company Summary

GT is a biotech start-up developing medical devices for CVD risk assessment, surgical therapy & hemorrhage control employing human clotting proteins. GT's flagship product, GammaCoeur, is a more predictive CVD test to guide physicians in developing preventive care programs. In 2016, GT won a $225,000 grant from the National Science Foundation to develop a fast-clotting hemorrhage control trauma dressing and is seeking a Phase II, $750 K grant.


  • Default avatar
    David Frederick Eastman, MS
    Chief Executive Officer

    35-year experienced Life Science industry executive developing & launching products & start-up ventures in medical devices, systems, & software; formerly interim CEO, Yecuris Corporation; prod mkt executive at Becton Dickinson, Cordis Dow Medical & Fresenius; OHSU Start Up Venture Advisory Group; BS in Mkt. & Comm, Univ. of No. Colorado; MS, Mkt., Bus, & Design, Univ. of OR., &; Exec. Medical Mkt. MBA Certificate, UCLA Anderson School of Mgmt..

  • Default avatar
    David Henry Farrell, PhD
    Founder & Chief Scientific Officer

    37-year researcher in thrombosis, hemostasis and coagulation research; 19 years as a Principal Investigator; Professor of Surgery, Department of Surgery, OHSU; Director, Health Sciences Entrepreneurship Certificate Program; Fellow of the American Heart Association; BS in Biochemistry, UCLA; PhD in Biological Sciences, Univ. of California, Irvine, Senior Fellow in Biochemistry, Univ. of Washington.


  • Default avatar
    Tonkon Torp
    Default avatar
    Candace Clement